Advertisement Protein Sciences gets FDA approval for Flublok influenza vaccine for adults aged 18 and older - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Protein Sciences gets FDA approval for Flublok influenza vaccine for adults aged 18 and older

US-based Protein Sciences has received approval from the US Food and Drug Administration (FDA) for Flublok influenza vaccine to treat adults aged 18 years and older.

Developed using modern recombinant technology, Flublok is the only flu vaccine that is 100% egg-free and highly purified.

Flublok also contains three times more active ingredients than traditional flu vaccines.

The vaccine is now indicated for use in people aged 50 years and older under the accelerated approval of biological products regulations.

Protein Sciences chief medical officer Lisa Dunkle said: "Older adults are known to be at high risk for contracting and developing complications from influenza."

Earlier in 2014, the US FDA has approved a shelf life extension for Flublok to six months.

Protein Sciences president and CEO Dr Manon Cox said: "We set out to develop a better vaccine for the older population by increasing the amount of active ingredients in the vaccine.

"People of all ages have been calling and asking for Flublok and now it is terrific to be able to (finally) tell them that the product is approved for all adults.

"Flublok is a modern vaccine with particular benefits to individuals who want (need) to avoid exposure to egg proteins, gelatin, latex, formaldehyde or antibiotics as Flublok is free of all of these unnecessary and avoidable components."

Currently, Flublok is available at Passport Health locations in the US and select pharmacies, clinics and doctor’s offices.